AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NBIX

Cooke Julie sold $5.8M of NBIX

Cooke Julie (Chief Human Resources Officer) sold 36,937 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at an average of $156.22 ($154.83–$158.59, $5.77M total) across 5 trades on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cooke Julie
Published Jun 4, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NBIX
Bearish
high confidence
Mentioned
$NBIX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXBearishLow
01

Why it matters

The $5.8M sale reduces insider ownership, potentially influencing short‑term sentiment.

02

Market read

Primary insider sale news for NBIX; modest trading relevance.

03

What to watch

Upcoming clinical trial data or partnership announcements could offset the sell‑off pressure.

Relevance 5/10Novelty 7/10Timing: after‑hours on 2026‑06‑04

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$NBIXBearishHigh confidence
Context

Chief Human Resources Officer Julie Cooke sold 36,937 shares for $5.77M via a 10b5‑1 plan, reducing her stake to 22,374 shares.

Expected impact

likely pressure as the market prices in the $5.8M insider sell

Evidence & confidence

Form 4 filings are primary source; a $5.8M sale by a senior officer is material for a mid‑cap biotech and can prompt short‑term selling.

Market effects

Sector

May raise concerns for biotech sector insiders, but limited to NBIX.

Regional

U.S. biotech investors may adjust positions; no broader regional effect.

Global

Minimal global impact beyond NBIX shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • Company
    Neurocrine Biosciences Inc.

    Biotech firm developing treatments for neurological and endocrine disorders.

  • Executive
    Julie Cooke

    Chief Human Resources Officer of Neurocrine Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NBIX insider trading history →

Related articles

$NBIXHighAI 8/10

NBIX Stock Jumps As Earnings Smash Estimates And Pipeline Expands

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

timothysykes.com
$NBIXHighAI 9/10

Why is Neurocrine Biosciences stock surging today?

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

investing.com
$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com